JBIO Stock Forecast: Jade Biosciences, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$15
+1.59% on the day

The median 12-month analyst price target for Jade Biosciences, Inc. is $46. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 40 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$1.1B
Ticker Nerd rank
40/ 100
Median analyst target
$46
Analysts covering
10
Revenue$0.0
Operating income−$58.9M
Net income−$55.8M
Free cash flow−$43.7M
Quarterly, 7 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.2%
1M
+3.0%
YTD
−0.8%
1Y
+33.3%
From 52W high
−43.0%
From 52W low
+33.3%
$11
$27
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Jade Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
40/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
72
Revisions
65
Volatility
64
Quality
57
Value
55
Growth
27
Issuance
23
Accruals
21

Momentum (72): The shares have been drifting up relative to others.

Accruals (21): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

JBIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on JBIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Jan 26Apr 26Jul 26Oct 26JBIOHigh $77Median $46Low $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
10
Buy
0
Hold
0
Sell
$40
Low
$46
Median
$77
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
16 Nov 2026GuggenheimMaintainsBuy$47 → $41
27 Oct 2026BTIGReiteratesBuy$77
1 Oct 2026HC Wainwright & Co.ReiteratesBuy$55
1 Oct 2026WedbushReiteratesOutperform$47
11 Aug 2026WedbushMaintainsOutperform$45 → $47
10 Aug 2026BTIGMaintainsBuy$74 → $77
15 June 2026UBSInitiatesBuy$45
2 June 2026WedbushMaintainsOutperform—
1 June 2026BTIGMaintainsBuy—
1 June 2026HC Wainwright & Co.MaintainsBuy—
27 May 2026BTIGReiteratesBuy—
11 May 2026GuggenheimMaintainsBuy—
11 May 2026WedbushMaintainsOutperform—
27 Apr 2026HC Wainwright & Co.MaintainsBuy—
25 Mar 2026HC Wainwright & Co.MaintainsBuy—
16 Mar 2026BTIGMaintainsBuy—
11 Mar 2026GuggenheimMaintainsBuy—
9 Mar 2026WedbushReiteratesOutperform—
7 Jan 2026HC Wainwright & Co.InitiatesBuy—
25 Nov 2025Clear StreetInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for JBIO.

Market Radar

This page is one stock. Monday covers all of them.

JBIO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

JBIO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Jade Biosciences, Inc. returned +33.3% against +6.9% for the S&P 500, dividends included.

JBIO vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Jan 26Apr 26Jul 26Oct 26JBIOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

JBIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
2.3×

Cheaper than 40% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−38.3%

Higher than 25% of US stocks

Return on assets
−36.4%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Jade Biosciences, Inc. has a market value of $1.1B and an enterprise value of $584.3M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$153.2M.

  • Free cash flow in the twelve months to 30 June 2026: −$123.6M.

  • Shares outstanding: 63.6M.

  • Jade Biosciences, Inc. employs 55 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

JBIO and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
JBIOJade Biosciences, Inc.$1.1B40
KARDKardigan, Inc.$1.1B3
DRTSAlpha Tau Medical Ltd.$1.1B15
SGPSpyGlass Pharma, Inc.$1.0B1
INBXInhibrx Biosciences, Inc.$1.0B37
NKTRNektar Therapeutics$1.0B40
CTYCity Therapeutics, Inc.$999.3M1

Take a look at JBIO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Jade Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about JBIO

What is the JBIO stock price forecast for 2026-2027?

The median 12-month analyst price target for Jade Biosciences, Inc. is $46, with estimates ranging from $40 to $77. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is JBIO stock a buy right now?

Of the 10 analysts covering Jade Biosciences, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Jade Biosciences, Inc. 40 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank JBIO?

As at 21 Nov 2026, Jade Biosciences, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (72 of 100).

Will JBIO stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts is $46, and Ticker Nerd's factor model ranks Jade Biosciences, Inc. 40 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the JBIO stock forecast for 2030?

No analyst covering Jade Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JBIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $77 over the next 12 months.

How has JBIO stock performed over the past year?

Jade Biosciences, Inc. returned +33.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Jade Biosciences, Inc. do?

Jade Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its current pipeline centers on antibody-based programs designed to target key immune pathways involved in conditions such as immunoglobulin A nephropathy and other inflammation-related disorders.

Company

About Jade Biosciences, Inc.

Jade Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its current pipeline centers on antibody-based programs designed to target key immune pathways involved in conditions such as immunoglobulin A nephropathy and other inflammation-related disorders. The company’s lead candidate, JADE101, is being developed to inhibit APRIL, a protein linked to abnormal immune activity, while JADE201 and JADE301 are advancing through earlier-stage research for additional autoimmune indications. Jade Biosciences works as a development-focused biopharmaceutical company, relying on clinical research, preclinical testing, and collaboration agreements to advance its programs. Headquartered in Waltham, Massachusetts, the company serves the immunology and nephrology fields by pursuing targeted biologic therapies for patients with significant unmet medical needs.

CEO Mr. Tom Frohlich · 55 employees · United States · https://jadebiosciences.com